Solid Tumor, Adult Clinical Trials in New York, New York

9 recruitingNew York, New York

Showing 19 of 9 trials

Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled31 locationsNCT06625775
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Solid Tumor, Adult
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Solid Tumor, Adult
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1Phase 2

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Solid Tumor, Adult
Linnaeus Therapeutics, Inc.200 enrolled10 locationsNCT04130516
Recruiting
Phase 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Solid Tumor, Adult
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 1Phase 2

Study of DF1001 in Patients with Advanced Solid Tumors

Solid Tumor, Adult
Dragonfly Therapeutics378 enrolled52 locationsNCT04143711
Recruiting
Phase 1Phase 2

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430